Neoadjuvant cemipimab for stage II to IV cutaneous squamous-cell carcinoma
Dr. Neil Gross
A multinational phase 2 nonrandomized study evaluated neoadjuvant cemiplimab for resectable stage II, III, of IV (M0) cutaneous cell carcinoma. Neoadjuvant cemiplimab resulted in response in a high percentage of patients, with pathological complete response in 51% and pathological major response in 13%. Grade 3 or higher adverse events during the neoadjuvant phase were observed in 18% of patients.
